Inguinal hernia surgery

TELA Bio Reports First Quarter 2024 Financial Results

Retrieved on: 
Giovedì, Maggio 9, 2024
Sale, PRS, Travel, Inguinal hernia surgery, Surgeon, Research, Matrix, FACS, Patient, Inguinal hernia, Event, MiMedx, Growth, Video game

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024.
  • Q1 was a strong quarter and we believe the rest of 2024 will continue to showcase the progress TELA is delivering on key strategic priorities.”
    Revenue was $16.6 million in the first quarter of 2024, an increase of 39% compared to the same period in 2023.
  • Operating expenses were $23.7 million in the first quarter of 2024, compared to $19.2 million in the same period in 2023.
  • TELA Bio will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 9, 2024 to discuss its first quarter 2024 financial results.

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

Retrieved on: 
Lunedì, Aprile 15, 2024
Inguinal hernia surgery, TAPP, Surgeon, Recurrence, Rumen, Patient, Inguinal hernia, Sheep, Rebar, Medical device

MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically designed for use in laparoscopic and robotic-assisted inguinal hernia repair.

Key Points: 
  • MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically designed for use in laparoscopic and robotic-assisted inguinal hernia repair.
  • Each configuration has been designed for trocar-compatibility to enhance use of these products in laparoscopic and robotic procedures.
  • “The inguinal hernia market has historically been dominated by permanent synthetic mesh with few viable alternatives to address the shortcomings of those materials.
  • With the introduction of OviTex IHR, we are addressing this need and providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response.”

The Inner Circle Acknowledges, Carrie Watson, DO, FACOS, FACS as a Top Pinnacle Healthcare Professional for her contributions to the Trauma Surgery Field

Retrieved on: 
Mercoledì, Ottobre 11, 2023
Level 3, Nursing care plan, Multimedia, FACS, Wound, Family, Hope, Osteopathic medicine in the United States, American College, Trauma center, Communication, Advanced trauma life support, University, OH, Hospital, Level 2, Trauma, Internal bleeding, DO, Fracture, ROCK, Associate, Environment, Injury, Anzac of the Year Award, Honors colleges and programs, UF Health Shands Hospital, Inguinal hernia surgery, University of Oklahoma College of Medicine, Surgeon, Rock Hill, South Carolina, Head Injuries, ICU, Shock, Philadelphia College of Osteopathic Medicine, Burns, Osteopathy, General surgery, Inner circle, Patient, Tetraplegia, Dentistry, Nursing, Psychology

ROCK HILL, S.C., Oct. 11, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Carrie Watson, DO, FACOS, FACS is acknowledged as a Top Pinnacle Healthcare Professional for her contributions to the Trauma Surgery Field.

Key Points: 
  • ROCK HILL, S.C., Oct. 11, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Carrie Watson, DO, FACOS, FACS is acknowledged as a Top Pinnacle Healthcare Professional for her contributions to the Trauma Surgery Field.
  • An exceptional resident, she was nationally recognized through the American College of Osteopathic Surgeons with the 2016 Resident Achievement Award.
  • A testament to her trauma surgery skills, she is also an instructor for Advanced Trauma Life Support.
  • She notes that trauma surgeons generally complete residency training in general surgery and often fellowship training in trauma or surgical critical care.

The Inner Circle Acknowledges, Carrie Watson, DO, FACOS as a Distinguished Healthcare Provider for her contributions to the Trauma Surgery Field

Retrieved on: 
Giovedì, Giugno 22, 2023
Internal bleeding, Communication, UF Health Shands Hospital, Surgeon, University, Education, Osteopathy, Advanced trauma life support, Philadelphia College of Osteopathic Medicine, OH, Shock, Hope, Trauma, Medicine, Level 2, Bone, Inner circle, DO, University of Oklahoma College of Medicine, Injury, ROCK, Honors colleges and programs, Inguinal hernia surgery, Patient, Physician, Rock Hill, South Carolina, General surgery, Hospital, Nursing care plan, ICU, Burns, American College, Piedmont, Environment, Family, Nursing, Dentistry, Psychology

ROCK HILL, S.C., June 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Carrie Watson, DO, FACOS, is acknowledged as a Distinguished Healthcare Provider for her contributions to the Trauma Surgery Field.

Key Points: 
  • ROCK HILL, S.C., June 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Carrie Watson, DO, FACOS, is acknowledged as a Distinguished Healthcare Provider for her contributions to the Trauma Surgery Field.
  • She capped her scholarship at the UF Health Shand's Hospital in Gainesville completing a surgical critical care fellowship.
  • According to Dr. Watson, trauma surgery is a specialty that utilizes both operative and non-operative management to treat traumatic injuries, typically in an acute setting.
  • She notes that trauma surgeons generally complete residency training in general surgery and often fellowship training in trauma or surgical critical care.

TELA Bio Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs; Data to Be Presented at 2022 American Hernia Society (AHS) Meeting

Retrieved on: 
Giovedì, Agosto 4, 2022
Diabetes, Medicine, Coronary artery disease, BRAVO, Private Securities Litigation Reform Act, Security (finance), SSO, Annual report, Rebar, Hernia, Recurrence, Quality of life, COPD, Foreign Bodies, AHS, Anatomy, 1S, Risk, Use, Patient, Company, Obesity, U.S. Securities and Exchange Commission, Surgical mesh, Sheep, Journal, Research, Solution, Health, Weakness, GLOBE, CEO, CDC, Surgeon, Abdominal wall, Inguinal hernia surgery, IceWall SSO, NASDAQ, Pharmaceutical industry, Medical imaging

MALVERN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that two studies examining clinical outcomes with use of its OviTex Reinforced Tissue Matrix will be presented at the 2022 American Hernia Society (AHS) Meeting.

Key Points: 
  • The conference, taking place from September 14-16, 2022, in Charlotte, North Carolina, will highlight the outcomes of two studies that underscore the efficacy of OviTex.
  • OviTex 1S Permanent demonstrated a 2.6% recurrence rate in ventral hernias repaired using open, laparoscopic, or robotic techniques at the 24-month time point.
  • These BRAVO 24-Month results follow the publication of the BRAVO 12-Month study, released in November 2021 in the Journal of Clinical Medicine .
  • OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists.

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

Retrieved on: 
Lunedì, Settembre 13, 2021
Inguinal hernia surgery, Society of American Gastrointestinal and Endoscopic Surgeons, Surgical mesh, U.S. Securities and Exchange Commission, Weakness, DO, Security (finance), Private Securities Litigation Reform Act, DRS, Medical research, Rebar, Marketing, Patient, Society, St. Francis Hospital, Use, Foreign body, Annual report, NASDAQ, Hernia, COVID-19, General surgery, MBA, Matrix, Sheep, GLOBE, Robot-assisted surgery, FACS, Recurrence, Risk, Goal, Journal, PRS, Maintenance, Abdominal wall, Medical imaging, Medical device

Two poster presentations revealed new data, while a third video presentation demonstrated a novel surgical technique that leverages the unique properties of OviTex Reinforced Tissue Matrix .

Key Points: 
  • Two poster presentations revealed new data, while a third video presentation demonstrated a novel surgical technique that leverages the unique properties of OviTex Reinforced Tissue Matrix .
  • Dr. Szotek stated, "The Reinforced Biologic Augmented Repair, or the ReBAR technique, applies sound hernia surgery principles while leveraging the benefits of a reinforced biologic material with a low synthetic foreign body burden.
  • Our initial goals in adopting OviTex were to lower recurrences while decreasing the amount of synthetic foreign body implanted.
  • Szotek and Banaschak employing the ReBAR technique was recently highlighted in an article entitled, Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR) published in the Journal of Clinical and Medical Research.

TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Presentations at SAGES 2021

Retrieved on: 
Lunedì, Agosto 16, 2021
NASDAQ, MBA, U.S. Securities and Exchange Commission, Inguinal, Sheep, Weakness, CEO, Robot-assisted surgery, Maintenance, Society, Risk, Private Securities Litigation Reform Act, Surgical mesh, Scleral reinforcement surgery, Society of American Gastrointestinal and Endoscopic Surgeons, Patient, COVID-19, GLOBE, Use, Rebar, Research, Marketing, Annual report, Security (finance), Inguinal hernia surgery, Matrix, Abdominal wall, Surgeon, Incisional hernia, Hernia, PRS, FACS, Medical imaging, Medical device, Glass fiber

(NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced three upcoming poster presentations on its OviTex Reinforced Tissue Matrix portfolio.

Key Points: 
  • (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced three upcoming poster presentations on its OviTex Reinforced Tissue Matrix portfolio.
  • Designed by leading experts, with collaboration from more than 100 surgeons, OviTex Reinforced Tissue Matrix is an advanced hernia repair technology that utilizes naturally sourced tissue reinforced with interwoven polymer fibers to facilitate tissue remodeling while optimizing strength and minimizing the foreign body inflammatory response.
  • TELA Bio's OviTex and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
  • OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists.

This Hernia Awareness Month, BG Medical and SURGIMESH Partners With CQInsights to Launch the First Hernia Patient-Centered Outcomes Initiative

Retrieved on: 
Martedì, Giugno 15, 2021
Medical Supplies, Technology, Manufacturing, Managed care, Health, Medical devices, Research, Software, Surgery, Science, Chemicals, Plastics, Clinical medicine, Medicine, Hernias, Medical specialties, Digestive system surgery, Hernia repair, Polypropylene, Mesh, Inguinal hernia surgery, Femoral hernia, BG Medical and SURGIMESH, CQ Insights, BG MEDICAL AND SURGIMESH, CQ INSIGHTS

Dr. Bruce Ramshaw, Past President of the Americas Hernia Society and Co-Founder of CQInsights, noted, I am thrilled that an organization of this size is willing to invest in the future of hernia surgery.

Key Points: 
  • Dr. Bruce Ramshaw, Past President of the Americas Hernia Society and Co-Founder of CQInsights, noted, I am thrilled that an organization of this size is willing to invest in the future of hernia surgery.
  • Innovative products and the ongoing multicenter clinical research will help better understand the magnitude of benefit this mesh provides to our patients undergoing hernia repair surgery.
  • SURGIMESH is the only non-woven polypropylene matrix mesh that promotes rapid and complete vascularized incorporation in just 12 days.
  • You should talk to your doctor about the potential benefits and risks and whether a hernia procedure is right for you.

TELA Bio Announces 12-Month Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair

Retrieved on: 
Giovedì, Marzo 18, 2021
Clinical medicine, Medicine, Medical specialties, Hernias, Digestive system surgery, Hernia repair, Surgical mesh, Surgery, Breast surgery, Inguinal hernia surgery, Incisional hernia

The analysis includes the full patient cohort at the 12-month follow-up and an interim cohort at the 24-month follow-up.

Key Points: 
  • The analysis includes the full patient cohort at the 12-month follow-up and an interim cohort at the 24-month follow-up.
  • The final 12-month analysis includes 76 patients, of whom two patients experienced a recurrence, both adjacent to the original repair, with the OviTex repairs remaining intact.
  • TELA Bio's OviTex and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
  • OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists.

Global Laparoscopic and Open Hernia Mesh Repair Surgery Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Dicembre 17, 2020
Surgery, Health, Clinical medicine, Medicine, Medical specialties, Digestive system surgery, Hernias, Acute pain, Laparoscopy, Surgery, Inguinal hernia surgery

The "Laparoscopic and Open Hernia Mesh Repair Surgery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Laparoscopic and Open Hernia Mesh Repair Surgery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 128-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • Amid the COVID-19 crisis, the global market for Laparoscopic and Open Hernia Mesh Repair Surgery estimated at US$3.2 Billion in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at a CAGR of 2.2% over the period 2020-2027.
  • The U.S. Market is Estimated at $948.1 Million, While China is Forecast to Grow at 1.8% CAGR
    The Laparoscopic and Open Hernia Mesh Repair Surgery market in the U.S. is estimated at US$948.1 Million in the year 2020.